Pyxis Oncology, Inc. Common Stock (PYXS)
Pyxis Oncology, Inc. is a biopharmaceutical company focused on developing targeted therapies for cancer treatment. It aims to leverage its proprietary platform to discover and advance novel therapeutics that improve outcomes for patients with difficult-to-treat cancers.
Company News
BOSTON, June 28, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, reported today that Pyxis Oncology’s Compensation Committee of the Board of Directors granted restricted stock units with respect to an aggregate of 89...
Pyxis Oncology (PYXS) delivered earnings and revenue surprises of 77.78% and 279.91%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Shares of Ulta Beauty, Inc. (NASDAQ: ULTA) fell sharply during Wednesday’s session amid the company's presentation at the J.P. Morgan Retail Roundup investor conference where the company reportedly issued a weak outlook. Ulta Beauty shares dipped 13.7% to $448.08 on Wednesday. Here are some other stocks moving in today's mid-day session. Gaine...
Pyxis Oncology is developing antibodies and antibody-drug conjugates for various tumor types. See why PYXS stock is a Hold.
Penny stocks to watch as sympathy momentum puts focus on stocks under $5 today. The post 3 Top Penny Stocks To Watch As GSIT, OMH Stock Explode appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.